[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Authors: P Genne, F Bichat, V Chiesa, G Griffon, M Bayssas, JL Beltramo, C Duvillard,
Oncodesign; Debiopharma ; Dijon Hospital
Abstract: Despite the theoretical advantages of a high local concentration of anticancer drugs, local chemotherapy often fails to produce a complete response. The main reason is the poor diffusion of drugs into tumor mass when injected inside or around tumor issues. L-OHP has proven to be effective in combination against many tumors in man, without nephrotoxicity. In this work, we determined the antitumor activity, pharmacokinetics (PKs) and biostribution of single intramural(IT) or intraperitoneal (IP) 1-OHP injections alone or combined with EP(1mg/kg), in BDIX rats bearing advanced DHD/K12/PROb peritoneal carcinomatoses or s.c. DHD/K12/PROb tumors.